Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Centaurus Therapeutics

2015 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
1 INVESTORS
Description

Developer of new therapeutics designed to combat the metabolic underpinnings of chronic diseases. The company's therapeutics contain small molecule inhibitors of a highly-validated target in the ceramide biosynthesis pathway, for the treatment of NASH, dyslipidemia, type 2 diabetes, and other metabolic diseases, enabling people to get therapeutic services and medicines to fight and cure orphan lipid storage diseases and fatty liver disease.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Services
Other Industries
Drug Discovery
Primary Office
  • DE
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Centaurus Therapeutics’s full profile, request a free trial.

Centaurus Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Centaurus Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Potrero Hill Therapeutics Venture Capital Minority 000 0000 000000 0

Centaurus Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Scott Summers Co-Founder & Scientific Advisor